FDA Authorizes Reformulated mRNA COVID-19 Vaccines for 2024-2025 Season

FDA Authorizes Updated 2024-2025 COVID-19 Vaccines Targeting KP.2 Variant

The FDA authorized updated 2024-2025 COVID-19 vaccines on August 22. The mRNA vaccines from Pfizer-BioNTech and Moderna target the KP.2 variant from the JN.1 lineage. Novavax's protein-based vaccine targets JN.1 itself. These formulations replace previous versions for the upcoming fall immunization campaign and reflect coordinated decisions across U.S. and global health bodies. [1][3]

What this means

The authorization allows production and distribution of the new vaccines in the United States. It follows the WHO's April 2024 guidance on the JN.1 lineage and aligns with CDC recommendations for broad use. Protection levels could vary if different variants rise later in the season. Post-authorization monitoring will gather data on how long immunity lasts and how the shots perform in real conditions.

Key takeaways

• The FDA authorized updated mRNA vaccines from Pfizer-BioNTech and Moderna that target KP.2, along with Novavax's JN.1-targeted vaccine, on August 22, 2024. [1]
• KP.2 belongs to the JN.1 lineage that the WHO recommended for antigen composition in its April 2024 statement. [3]
• CDC recommendations call for an updated COVID-19 vaccine for everyone 6 months and older. [2]
• Regulators based the authorization on immunogenicity data and established safety profiles from prior formulations rather than new variant-specific efficacy trials. [1]
• FDA, CDC, and WHO positions support annual updates to vaccine antigens to address dominant circulating variants. [1][2][3]

The FDA relied on its Vaccines and Related Biological Products Advisory Committee for input on strain selection. Committee members reviewed circulation data from spring and summer 2024. KP.2 demonstrated a solid antigenic match during laboratory evaluations.

The WHO issued its statement on April 26, 2024. That document advised use of an antigen from the JN.1 lineage. [3] U.S. regulators chose the KP.2 descendant for the mRNA vaccines.

The updated vaccines carry safety expectations similar to those of earlier versions. The FDA used bridging studies focused on immune responses instead of new large-scale efficacy trials. [1]

The CDC maintains its guidance page on COVID-19 vaccines. Following the FDA action the page now ties its recommendations to the 2024-2025 formulations for everyone six months and older. Most people need just one dose. Further details on pediatric schedules will come in later updates. [2]

Vaccine makers have indicated shipments will begin in the near term. Specific availability timelines for clinics and pharmacies remain subject to final logistics.

Limitations

Authorization relies on immunogenicity data and prior safety profiles rather than variant-specific clinical efficacy trials. Circulating SARS-CoV-2 variants may shift by peak respiratory season, potentially affecting real-world match. Long-term duration of protection and comparative effectiveness versus prior formulations will require post-authorization surveillance. Vaccine availability, uptake rates, and specific pediatric dosing details will be clarified in subsequent CDC clinical guidance.

FAQ

Which manufacturers' updated COVID-19 vaccines were authorized by the FDA for 2024-2025?
Pfizer-BioNTech and Moderna received authorization for their KP.2-targeted mRNA vaccines. Novavax received authorization for its JN.1-targeted protein-based vaccine. [1]

What specific SARS-CoV-2 variant is the primary target of the updated mRNA formulations?
The primary target is KP.2, a variant within the JN.1 lineage. [1]

How does the new vaccine composition align with CDC recommendations and global strain selection guidance?
The composition follows the WHO’s April 2024 recommendation to use a JN.1 lineage antigen. The CDC has updated its guidance to align with the FDA authorization. [2][3]

What is the expected availability and recommended use for these updated vaccines?
The vaccines replace prior formulations for the fall 2024 campaign. Recommendations include use in everyone 6 months and older. [2]

Sources / References

1. FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants. https://www.fda.gov/news-events/press-announcements/fda-takes-action-updated-mrna-covid-19-vaccines-better-protect-against-currently-circulating

2. Stay Up to Date with COVID-19 Vaccines. https://www.cdc.gov/covid/vaccines/stay-up-to-date.html

3. Statement on the antigen composition of COVID-19 vaccines. https://www.who.int/news/item/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines